Personalized metabolic insights, now available OTC
The weight of the news: FDA clears first OTC CGM for weight management
There are moments in health care when I pause, take a breath, and truly feel the ground shift beneath us. The FDA’s recent clearance of the Signos Glucose Monitoring System is one of those moments. For the first time, adults seeking to manage their weight (without the need for insulin) have access to an over the counter, continuous glucose monitor (CGM) designed just for them (Pharmacy Times, 2025).
No prescription. No complicated hoops to jump through. Just science, actionable insights, and a practical path to better health.
How Signos works: Turning body data into real change
The Signos system combines Dexcom’s Stelo biosensor with a smart, AI-powered mobile app (Medical Economics, 2025). Here’s what that means in practice:
- Real time metabolic feedback: See how your food, exercise, sleep, and even stress affect your glucose levels, moment to moment.
- Personalized, actionable suggestions: AI interprets your glucose fluctuations, offering recommendations for food choices, activity, sleep tweaks, and more.
- Built for everyday life: The app turns medical data into guidance you can use at the grocery store, on your morning walk, or when winding down at night.
Imagine watching your body respond to that afternoon snack or late night Netflix binge. Now, imagine having a friendly digital coach in your pocket, suggesting a better choice, backed by your own biology.
Making metabolic health truly accessible
We’re living in an era where more than 73% of U.S. adults are overweight or obese (Drugs.com, 2025). For many, the tools to understand and manage their weight have felt out of reach and even worse, locked behind prescriptions and insurance red tape.
Signos changes that. Here’s the breakdown:
- No prescription required
- All in subscription pricing, including sensors and accessories:
- 3-month plan: ~$139/month
- 6-month plan: ~$129/month (Drug Topics, 2025)
- 3-month plan: ~$139/month
It’s a practical step forward, making metabolic feedback attainable for millions who might have otherwise been left behind.
The science: Motivation that sticks
Data isn’t just about numbers, it’s about motivation. Studies show that about 87% of CGM users change their eating habits, and nearly half become more active, simply by seeing their body’s response in real time (Pharmacy Times, 2025).
This is more than a gadget. As Signos CEO Sharam Fouladgar-Mercer put it, “Everyone deserves access to insights that help them live healthier, longer, more vibrant lives. Signos isn’t just about data; it’s about giving people ownership over their health and weight journeys” (Medical Economics, 2025).
The role of pharmacists: From dispenser to health guide
This OTC clearance isn’t just a win for users, it’s a new opportunity for pharmacists, too.
- Counseling: Guiding patients on sensor use and interpreting their data.
- Coaching: Helping connect glucose insights to smarter dietary and activity choices.
- Bridging care: Supporting those using Signos alongside other therapies, like GLP-1 medications or bariatric surgery (Verywell Health, 2025; Healthline, 2025).
If you’re a pharmacist, consider this: How might your counsel evolve as more patients arrive, curious about integrating tech like Signos into their wellness plans?
Reflect and act: What will you do with this new tool?
If you’re managing your weight, would seeing your glucose data change the way you eat or move?
If you’re a pharmacist or healthcare provider, how might you use these insights to spark real conversations about health?
The future of weight management isn’t just about willpower. It’s about wisdom, support, and meeting people where they are. Signos is a step in that direction.
Drug Topics. (2025, August 21). FDA clears OTC glucose monitor for weight management.
Healthline. (2025, August 21). Signos glucose monitoring system for weight loss receives FDA clearance.
Investor’s Business Daily. (2025, August 21). Dexcom breaks out as FDA clears it to enter a new market: Obesity.
Medical Economics. (2025, August 22). Signos launches first FDA-cleared over-the-counter glucose monitoring system for weight management.
Pharmacy Times. (2025, August 21). CGM system for weight loss receives FDA clearance.
Verywell Health. (2025, August 22). FDA clears Signos glucose monitoring system for weight management.
